Demographic and serological data
| Controls (n=202) | NDBE (n=38) | HGD/IMC (n=18) | Total* (N=258) | P value | ||
| Sex | Male, (%) | 77 (38.1) | 31 (81.6) | 15 (83.3) | 123 (47.7) | < 0.001 |
| Age | Years, median (range) | 55.5 (20–91) | 67.0 (35–88) | 65.5 (50–79) | 58.0 (20–91) | < 0.001 |
| Helicobacter pylori | Positive (%) | 34 (16.8) | 3 (7.9) | 3 (16.7) | 40 (15.5) | 0.409 |
| Barrett’s length | cm, median (range) | 0 (0–0.5) | 4 (1–16) | 5 (1–14) | 0 (0–15) | < 0.001 |
| BMI | kg/m2, median (range) | 26.4 (16.5–45.0) | 28.3 (21.7–43.9) | 28.4 (22.9–36.4) | 26.8 (16.5–45.0) | 0.008 |
| Smoker | Positive (%) | 26 (12.9) | 3 (7.9) | 3 (16.7) | 32 (12.4) | 0.570 |
| Heavy drinker | Positive (%) | 19 (9.4) | 8 (21.1) | 2 (11.1) | 29 (11.2) | 0.091 |
| PPI use | Positive (%) | 125 (61.9) | 33 (86.6) | 17 (94.4) | 175 (67.8) | < 0.001 |
| PG1 | ng/mL, median (range) | 100.7 (6.05–500) | 286.8 (58.4–500) | 312.2 (132.3–500) | 124.2 (6.1–500) | < 0.001 |
| PG2 | ng/mL, median (range) | 6.0 (0.8–60) | 12.8 (3.2–25.7) | 17.5 (7.7–60) | 7.24 (0.8–60) | < 0.001 |
| G17 | ng/mL, median (range) | 4.8 (0–50) | 12.7 (0–50) | 15.2 (0–50) | 6.5 (0.0–50.0) | 0.004 |
| TFF3 | ng/mL, median (range) | 7.3 (0.6–31.3 | 7.5 (2.1–11.7) | 7.3 (4.1–12.2) | 7.3 (0.6–31.3) | 0.979 |
| PG1 <50 ng/mL | Positive (%) | 26 (12.9) | 0 (0.0) | 0 (0.0) | 26 (10.1) | 0.011 |
| G17 >10 ng/mL | Positive (%) | 75 (37.1) | 20 (52.6) | 12 (66.7) | 107 (41.5) | 0.017 |
| TFF3 >7 pg/mL | Positive. (%) | 101 (54.3) | 20 (52.6) | 9 (50.0) | 130 (53.7) | 0.921 |
*Patients with Barrett’s oesophagus indefinite for dysplasia have been excluded from this part of the analysis. P-values are printed in bold if statistically significant in group comparison.
BMI, body mass index; G17, gastrin-17; HGD/IMC, high-grade dysplasia or intramucosal cancer; NDBE, non-dysplastic Barrett’s oesophagus; PG, pepsinogen; PPI, proton pump inhibitor; TFF3, trefoil factor 3.